Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
Without taking into account existing biomarkers like genetic mutations (BRCA mutation, Homologous recombination deficiency) with advanced ovarian cancer (OC), the overall survival (OS), progress-free survival (PFS) of the aggregate all groups that have been classified were hazard ratio (HR): 0.72, 9...
Збережено в:
| Автор: | |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Taylor & Francis Group
2023-12-01
|
| Серія: | Journal of Obstetrics and Gynaecology |
| Предмети: | |
| Онлайн доступ: | http://dx.doi.org/10.1080/01443615.2023.2171282 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|